These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). Crowley J; Thaçi D; Joly P; Peris K; Papp KA; Goncalves J; Day RM; Chen R; Shah K; Ferrándiz C; Cather JC J Am Acad Dermatol; 2017 Aug; 77(2):310-317.e1. PubMed ID: 28416342 [TBL] [Abstract][Full Text] [Related]
3. Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis. Haber SL; Hamilton S; Bank M; Leong SY; Pierce E Ann Pharmacother; 2016 Apr; 50(4):282-90. PubMed ID: 26783350 [TBL] [Abstract][Full Text] [Related]
4. Management of Common Side Effects of Apremilast. Langley A; Beecker J J Cutan Med Surg; 2018; 22(4):415-421. PubMed ID: 29290125 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242 [TBL] [Abstract][Full Text] [Related]
6. Real-world use of apremilast for patients with psoriasis in Japan. Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880 [TBL] [Abstract][Full Text] [Related]
7. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting. Radi G; Campanati A; Diotallevi F; Molinelli E; Offidani A G Ital Dermatol Venereol; 2019 Apr; 154(2):166-169. PubMed ID: 30229640 [TBL] [Abstract][Full Text] [Related]
8. [Gastrointestinal side effects of apremilast : Characterization and management]. Pinter A; Beigel F; Körber A; Homey B; Beissert S; Gerdes S; Staubach-Renz P; Radtke MA; Mössner R Hautarzt; 2019 May; 70(5):354-362. PubMed ID: 30937481 [TBL] [Abstract][Full Text] [Related]
9. Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Deeks ED Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911 [TBL] [Abstract][Full Text] [Related]
10. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis. Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418 [TBL] [Abstract][Full Text] [Related]
11. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL. Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231 [TBL] [Abstract][Full Text] [Related]
13. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812 [TBL] [Abstract][Full Text] [Related]
14. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258 [TBL] [Abstract][Full Text] [Related]
15. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233 [TBL] [Abstract][Full Text] [Related]
16. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657 [TBL] [Abstract][Full Text] [Related]
17. Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis. Prescrire Int; 2016 Jun; 25(172):149-51. PubMed ID: 27486641 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702 [TBL] [Abstract][Full Text] [Related]
20. Apremilast for psoriasis treatment. Carrascosa JM; Del-Alcazar E G Ital Dermatol Venereol; 2020 Aug; 155(4):421-433. PubMed ID: 32545946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]